Kronos Bio (KRON)
(Delayed Data from NSDQ)
$1.15 USD
+0.02 (1.77%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $1.16 +0.01 (0.87%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRON 1.15 +0.02(1.77%)
Will KRON be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KRON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRON
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
KRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Other News for KRON
12 Health Care Stocks Moving In Thursday's Intraday Session
Video: Thursday 6/13 Insider Buying Report: KRON, PEB
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
12 Health Care Stocks Moving In Tuesday's Intraday Session
Kronos Bio: Still Promising But Riskier Following ASCO Update